Literature DB >> 9664198

A practical guide to prescribing hormone replacement therapy.

K A McKinney1, W Thompson.   

Abstract

Over the past 20 years there has been increasing interest in the menopause and hormone replacement therapy (HRT). More recently, postmenopausal HRT has been seen as a specific treatment for symptoms in the short term and preventative therapy in the long term. Women must be counselled regarding the risks and benefits of HRT according to the best available evidence. The patient should also be actively involved in the decision regarding HRT therapy, which should then improve patient compliance. Generally, an appropriate regimen of HRT can be formulated for the majority of patients. Progestogen should be added to therapy in women with an intact uterus in a cyclical or continuous regimen. The management of common estrogenic and progestogenic adverse effects is important in improving compliance. At present, new drugs are being developed for the management of the menopause (selective estrogen receptor modulators and phytoestrogens). Obviously, further research will be necessary to determine whether these drugs have advantages over regular HRT. By offering postmenopausal women HRT an attempt is made to optimise their physical and psychological well-being. However, HRT is not without adverse effects, the most worrying of which is the possible increase in breast cancer risk with long term use. However, with patient education efforts, treatment regimens acceptable to both patient and practitioner can be initiated; in this regard, the aim of the practitioner should be to help the menopausal woman make the decision which is the most appropriate for her.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9664198     DOI: 10.2165/00003495-199856010-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  29 in total

1.  Hormone replacement therapy in women with liver disease.

Authors:  J O'Donohue; R Williams
Journal:  Br J Obstet Gynaecol       Date:  1997-01

2.  Treatment of menopausal symptoms in breast cancer patients.

Authors:  B A Stoll; S Parbhoo
Journal:  Lancet       Date:  1988-06-04       Impact factor: 79.321

3.  Estrogen therapy arrests bone loss in elderly women.

Authors:  M E Quigley; P L Martin; A M Burnier; P Brooks
Journal:  Am J Obstet Gynecol       Date:  1987-06       Impact factor: 8.661

4.  Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins.

Authors:  D Crook; M P Cust; K F Gangar; M Worthington; T C Hillard; J C Stevenson; M I Whitehead; V Wynn
Journal:  Am J Obstet Gynecol       Date:  1992-03       Impact factor: 8.661

5.  The role of androgen in the maintenance of sexual functioning in oophorectomized women.

Authors:  B B Sherwin; M M Gelfand
Journal:  Psychosom Med       Date:  1987 Jul-Aug       Impact factor: 4.312

6.  Health status and utilization behavior associated with menopause.

Authors:  J B McKinlay; S M McKinlay; D J Brambilla
Journal:  Am J Epidemiol       Date:  1987-01       Impact factor: 4.897

7.  Risk of venous thromboembolism in users of hormone replacement therapy.

Authors:  E Daly; M P Vessey; M M Hawkins; J L Carson; P Gough; S Marsh
Journal:  Lancet       Date:  1996-10-12       Impact factor: 79.321

Review 8.  Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.

Authors:  J P Vandenbroucke; F M Helmerhorst; K W Bloemenkamp; F R Rosendaal
Journal:  Am J Obstet Gynecol       Date:  1997-10       Impact factor: 8.661

9.  Hormone replacement therapy in previously treated breast cancer patients.

Authors:  A G Wile; R W Opfell; D A Margileth
Journal:  Am J Surg       Date:  1993-03       Impact factor: 2.565

10.  Estrogen use and blood pressure in later life.

Authors:  R I Pfeffer; T T Kurosaki; S K Charlton
Journal:  Am J Epidemiol       Date:  1979-10       Impact factor: 4.897

View more
  6 in total

Review 1.  Long-term hormone therapy for perimenopausal and postmenopausal women.

Authors:  Jane Marjoribanks; Cindy Farquhar; Helen Roberts; Anne Lethaby; Jasmine Lee
Journal:  Cochrane Database Syst Rev       Date:  2017-01-17

2.  Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.

Authors:  Dinesh Vyas; Nicolas Lopez-Hisijos; Sulakshana Gandhi; M El-Dakdouki; Marc D Basson; Mary F Walsh; X Huang; Arpita K Vyas; Lakshmi S Chaturvedi
Journal:  J Nanosci Nanotechnol       Date:  2015-09

Review 3.  Estradiol-intranasal: a review of its use in the management of menopause.

Authors:  M Dooley; C M Spencer; D Ormrod
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Vaginal rings for menopausal symptom relief.

Authors:  Susan A Ballagh
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 5.  Pituitary disorders. Drug treatment options.

Authors:  J J Orrego; A L Barkan
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

6.  Ovarian survival after pelvic radiation: transposition until the age of 35 years.

Authors:  Ellen J Hoekman; Dan Knoester; Alexander A W Peters; Frank W Jansen; Cornelis D de Kroon; Carina G J M Hilders
Journal:  Arch Gynecol Obstet       Date:  2018-09-14       Impact factor: 2.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.